Patients diagnosed with chronic disease/illness precluding their participation (i.e., diabetics receiving insulin, myocardial infarction or unstable angina within previous 6 months, chronic hepatitis, rheumatoid disease, renal or hepatic disease/dysfunction)Xx_NEWLINE_xXPatients who have a significant history of cardiac disease, i.e., uncontrolled hypertension, unstable angina, congestive heart failure, or uncontrolled arrhythmias within 6 months of registrationXx_NEWLINE_xXHistory of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmiasXx_NEWLINE_xXHistory of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmiasXx_NEWLINE_xXSevere, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of study entry* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of study entry * Coagulation defects; note, however, that coagulation parameters are not required for entry into this protocolXx_NEWLINE_xXSevere, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol* Acquired immune deficiency syndrome (AIDS) based upon the current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patientsXx_NEWLINE_xXSevere, active co-morbidity, defined as follows per time points indicated below (or per time points indicated below prior to the first day of chemotherapy for patients having started chemotherapy prior to first step registration): * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the 3 months of study registration* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registrationXx_NEWLINE_xXSevere, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects or severe liver dysfunction* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patientsXx_NEWLINE_xXNew York Heart Association (NYHA) classification III or IV congestive heart failureXx_NEWLINE_xXHistory of coronary artery disease (angina or myocardial infarction)Xx_NEWLINE_xXSevere, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of study entry* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of study entry* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; hepatic or biliary disease that is acute or currently active or that requires antiviral therapy (with the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per investigator assessment)* History of left ventricular ejection fraction (LVEF) below institutional normal unless repeated and within institutional normal range within 90 days of study entryXx_NEWLINE_xXPatients must not have clinically significant illness including uncontrolled, active infection requiring intravenous antibiotics, New York Heart Association (NYHA) class III or class IV heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled >= grade 3 cardiac arrhythmias, uncontrolled hypertension, or uncontrolled diabetes mellitus; patients must have undergone an electrocardiogram (EKG) within 28 days prior to registrationXx_NEWLINE_xXSevere, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months PRIOR TO registration* Transmural myocardial infarction within the last 6 months prior to study entry* Unstable ventricular arrhythmia within the last 6 months prior to study entry* Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry* Hepatic insufficiency resulting in clinical jaundice, encephalopathy and/or variceal bleed within 28 days prior to study entry* Bleeding within 28 days prior to study entry due to any cause, requiring transfusion* Thrombolytic therapy within 28 days prior to study entry; subcutaneous heparin is permitted* Known bleeding or clotting disorder* Uncontrolled psychotic disorderXx_NEWLINE_xXPatients must not have cardiovascular risk factors including unstable angina, history of documented myocardial infarction or cerebrovascular accident, coronary artery bypass surgery, or New York Heart Association class III or IV heart failure; patients must not have known uncontrolled hyperlipidemia (defined as low-density lipoprotein cholesterol [LDL-C] >= 190 mg/dL or triglycerides >= 500 mg/dL) within the last 3 years prior to registration or uncontrolled high blood pressure (systolic blood pressure > 150 mm Hg) within 28 days prior to registrationXx_NEWLINE_xXSTEP I: Patients should not have New York Heart Association classification III or IV heart failure or myocardial infarction within the previous 6 monthsXx_NEWLINE_xXSignificant cardiovascular disease defined as congestive heart failure (New York Heart Association class III or IV cardiac disease), angina pectoris requiring nitrate therapy or recent myocardial infarction (=< 6 months prior to registration)Xx_NEWLINE_xXPatients with symptoms of congestive heart failure are not eligibleXx_NEWLINE_xXMedical illness unrelated to HL, which in the opinion of the study physician will preclude administration of chemotherapy safely; this includes patients with uncontrolled infection (including opportunistic), chronic renal failure, myocardial infarction (MI) within the past 6 months, unstable angina, or cardiac arrhythmias other than chronic atrial fibrillation, or second malignancy requiring active treatmentXx_NEWLINE_xXSevere, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, coagulation parameters are not required for entry into this protocol* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol* Pre-existing >= grade 2 neuropathy* Prior organ transplantXx_NEWLINE_xXSevere, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to registration* Transmural myocardial infarction within 6 months prior to registration* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration* Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy or is thought to require oxygen therapy within 1 year prior to registration* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patientsXx_NEWLINE_xXSevere, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration; hepatic insufficiency resulting in clinical jaundice and/or coagulation defects* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patientsXx_NEWLINE_xXThe subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:* Cardiovascular disorders including:** Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening** Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mmHg systolic, or > 90 mmHg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment** Any history of congenital long QT syndrome** Any of the following within 6 months before the first dose of study treatment:*** Unstable angina pectoris*** Clinically-significant cardiac arrhythmias*** Stroke (including transient ischemic attack [TIA], or other ischemic event)*** Myocardial infarction*** Thromboembolic event requiring therapeutic anticoagulation (note: subjects with a venous filter [e.g. vena cava filter] are not eligible for this study)Xx_NEWLINE_xXCardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association class III or IV), active angina pectoris, or recent myocardial infarction (within the last 6 months)Xx_NEWLINE_xXPatients must not have New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemiaXx_NEWLINE_xXPatients must not have a myocardial infarction within 6 months prior to registrationXx_NEWLINE_xXCardiac function:* Known inherited coronary disease* Symptomatic heart failure (New York Heart Association [NYHA] class II-IV prior or current cardiomyopathy, or severe valvular heart disease)* Prior or current cardiomyopathy* Severe valvular heart disease* History of atrial fibrillationXx_NEWLINE_xXThe following groups of patients are eligible after consultation with a cardiologist and at the coordinating center PI�s discretion, provided they have New York Heart Association class II (NYHA) cardiac function on baseline echocardiogram (ECHO)/multigated acquisition scan (MUGA):* Those with a history of class II heart failure who are asymptomatic on treatment* Those with prior anthracycline exposure greater than a cumulative dose of 350 mg/m^2* Those who have received central thoracic radiation that included the heart in the radiotherapy portXx_NEWLINE_xXPatients with cardiac diseases ongoing or in the past 6 months (e.g. congestive heart failure, acute myocardial infarction, significant uncontrolled arrhythmias) are not eligible for this trialXx_NEWLINE_xXAdequate cardiac function, defined as:* No electrocardiogram (EKG) evidence of acute ischemia* No EKG evidence of active, clinically significant conduction system abnormalities* No EKG evidence of > grade 2 (> 480 ms) corrected QT (QTc) prolongation * Prior to study entry, any EKG abnormality at screening not felt to put the patient at risk has to be documented by the investigator as not medically significant* No uncontrolled angina or severe ventricular arrhythmias* No clinically significant pericardial disease* No history of myocardial infarction within 6 months prior to registration* No class 3 or higher New York Heart Association congestive heart failureXx_NEWLINE_xXAtherosclerotic cardiovascular disease (ASCVD) defined by history of acute coronary syndromes, myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial disease presumed to be of atherosclerotic originXx_NEWLINE_xXSevere, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months;* Transmural myocardial infarction within the last 6 months;* Chronic obstructive pulmonary disease exacerbation or other respiratory illness other than the diagnosed lung cancer requiring hospitalization or precluding study therapy within 30 days before registration;* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocolXx_NEWLINE_xXClass II or greater congestive heart failure as described in the New York Heart Association Functional Classification criteria or serious arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmias requiring chronic therapy)Xx_NEWLINE_xXPatient must have no history of recent myocardial infarction (within three months), uncontrolled congestive heart failure, or uncontrolled cardiac arrhythmiaXx_NEWLINE_xXAny condition associated with increased risk of metformin-associated lactic acidosis; (e.g. congestive heart failure defined as New York Heart Association [NYHA] class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)Xx_NEWLINE_xXClinically significant cardiomyopathy or cardiac complications, including recent myocardial infarction or cerebrovascular accident within one year, and/or unstable or uncontrolled anginaXx_NEWLINE_xXSubject has a significant history of cardiovascular disease (e.g., myocardial infarction [MI], thrombotic or thromboembolic event in the last 6 months)Xx_NEWLINE_xXPatients with cardiac diseases ongoing or in the past 6 months (e.g. congestive heart failure, acute myocardial infarction, significant uncontrolled arrhythmias) are not eligible for this trialXx_NEWLINE_xXNo history of any of the following =< 6 months of registration:* Myocardial infarction or unstable angina* New York Heart Association grade III or greater congestive heart failure * Cerebrovascular accident * Grade 3 or 4 peripheral ischemia* Grade 3 or 4 thromboembolic eventXx_NEWLINE_xXSevere, active co-morbidity, defined as follows:* Major medical or psychiatric illness, which in the investigator�s opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy* Unstable angina and/or uncontrolled congestive heart failure* Myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; note that patients switched from IV antibiotics and currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocolXx_NEWLINE_xXNo history of the following:* Class III or IV congestive heart failure (CHF)* Grade 3 or 4 thromboembolic event =< 6 months* Pericardial effusion =< 12 months (any grade)* Pericardial involvement with tumor* Grade 2 or higher pleural effusion =< 6 monthsXx_NEWLINE_xXNo history of the following:* Class III or IV congestive heart failure (CHF)* Pericardial effusion =< 12 months (grade 3 or 4)* Pericardial involvement with tumor* Grade 2 or higher pleural effusion =< 6 monthsXx_NEWLINE_xXHistory of cardiovascular disease (e.g., myocardial infraction [MI], thrombotic or thromboembolic event in the last 6 months)Xx_NEWLINE_xXSevere, active co-morbidity, defined as follows:* Unstable angina at step 2 registration* Transmural myocardial infarction within the last 6 months prior to step 2 registration * Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of >= 2 mm using the analysis of an electrocardiogram (EKG) performed within 28 days prior to step 2 registration (Note: EKG to be performed only if clinical suspicion of cardiac issue)* New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to step 2 registration* Serious and inadequately controlled arrhythmia at step 2 registration* Serious or non-healing wound, ulcer or bone fracture or history of abdominal fistula, intra-abdominal abscess requiring major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to step 2 registration, with the exception of the craniotomy for surgical resection * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step 2 registration* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step 2 registration* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol* Any other severe immunocompromised condition* Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity* End-stage renal disease (ie, on dialysis or dialysis has been recommended)* Any other major medical illnesses or psychiatric treatments that in the investigator�s opinion will prevent administration or completion of protocol therapyXx_NEWLINE_xXNew York Heart Association class III or greater congestive heart failure within last 6 months or uncontrolled hyperlipidemia (cholesterol > 300 mg/dl; triglyceride 2.5 X upper limit of normal [ULN] despite lipid lowering agent) within last 3 monthsXx_NEWLINE_xXHeart failure >= New York Heart Association (NYHA) grade 3Xx_NEWLINE_xXAcute myocardial infarction =< 12 months prior to starting drugXx_NEWLINE_xXSubjects with any of the following cardiovascular conditions within the past 6 months* Cerebrovascular accident (CVA) or transient ischemic attack (TIA)* Cardiac arrhythmia* Admission for unstable angina* Cardiac angioplasty or stenting* Coronary artery bypass graft surgery* Pulmonary embolism, untreated deep venous thrombosis (DVT) or DVT which has been treated with therapeutic anticoagulation for less than 6 weeks* Arterial thrombosis* Symptomatic peripheral vascular disease* Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system; a subject who has a history of class II heart failure and is asymptomatic on treatment may be considered eligibleXx_NEWLINE_xXCurrently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction unstable angina, or acute coronary syndrome within 6 months prior to enrollment in the studyXx_NEWLINE_xXSevere, active co-morbidity defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registrationXx_NEWLINE_xXHistory within 6 months prior to treatment of myocardial infarction, severe/unstable angina pectoris, coronary artery bypass graft (CABG), New York Heart Association (NYHA) class III or IV congestive heart failure (CHF), stroke or transient ischemic attack (TIA)Xx_NEWLINE_xXCardiovascular disorders including:* Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening* Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment* The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms within 28 days before randomization; Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed; if the average of these three consecutive results for QTcF is =< 500 ms, the subject meets eligibility in this regard* Any history of congenital long QT syndrome* Any of the following within 6 months before the first dose of study treatment:** Unstable angina pectoris** Clinically-significant cardiac arrhythmias** Stroke (including transient ischemic attack [TIA], or other ischemic event)** Myocardial infarction** CardiomyopathyXx_NEWLINE_xXPatients must not have a history of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of 3, unstable angina or poorly controlled arrhythmia or myocardial infarction within 6 months prior to registration; if clinically indicated, echocardiogram or multigated acquisition (MUGA) must be performed and cardiac ejection fraction must be >= 50%Xx_NEWLINE_xXCardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens; this includes but is not confined to:* Active cardiac disease** Angina pectoris that requires the current use of anti-anginal medication;** Ventricular arrhythmias except for benign premature ventricular contractions;** Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication;** Conduction abnormality requiring a pacemaker;** Valvular disease with documented compromise in cardiac function; or** Symptomatic pericarditis* History of cardiac disease** Myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricle (LV) function;** History of documented congestive heart failure (CHF); or** Documented cardiomyopathyXx_NEWLINE_xXUnstable angina, myocardial infarction or New York Heart Association (NYHA) class III/IV congestive heart failure within 30 days preceding study enrollmentXx_NEWLINE_xXNo congestive heart failure (CHF) within 182 days of registrationXx_NEWLINE_xXNo angina or myocardial infarction within 182 days of registration; in view of potential cardiac risk with lenalidomide, patients with stable angina will be excludedXx_NEWLINE_xXKnown cardiac disorder, including:* Known inherited coronary disease* Symptomatic heart failure (New York Heart Association [NYHA] class II-IV prior or current cardiomyopathy, or severe valvular heart disease)* Current cardiomyopathy* Severe valvular heart disease* Atrial fibrillation* Ejection fraction (ECHO) < 53%* QTcF > 450 msecXx_NEWLINE_xXHistory (within the previous year) of stroke or transient ischemic attack, unstable angina, myocardial infarction, hospitalization for acutely decompensated congestive heart failureXx_NEWLINE_xXPatients with a history of the following within =< 12 months of study entry are not eligible:* Arterial thromboembolic events* Unstable angina* Myocardial InfarctionXx_NEWLINE_xXPatients with any of the following:* History of myocardial infarction within six months* Unstable angina* Resting electrocardiogram (ECG) with clinically significant abnormal findings* New York Heart Association (NYHA) classification of III or IVXx_NEWLINE_xXIf cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines* Patients with the following risk factors should have a baseline cardiac function assessment:** Prior treatment with anthracyclines** Prior treatment with trastuzumab** Prior central thoracic radiation therapy (RT), including RT to the heart** History of myocardial infarction within 6 to 12 months (patients with history of myocardial infarction within 6 months are excluded from the study)** Prior history of impaired cardiac functionXx_NEWLINE_xXPatients with any of the following:* History of myocardial infarction within six months* Unstable angina* Resting electrocardiogram (ECG) with clinically significant abnormal findings* New York Heart Association functional classification of III or IVXx_NEWLINE_xXIf cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines* Patients with the following risk factors should have a baseline cardiac function assessment:** Prior treatment with anthracyclines** Prior treatment with trastuzumab** Prior central thoracic radiation therapy (RT), including RT to the heart** History of myocardial infarction within 6 to 12 months (Patients with history of myocardial infarction within 6 months are excluded from the study)** Prior history of impaired cardiac functionXx_NEWLINE_xXPatients with known cardiac disease per the New York Heart Association definition such as myocardial infarction, severe or unstable angina, peripheral vascular disease, or congestive heart failure or peripheral vascular disease are not eligibleXx_NEWLINE_xXPatients who have the following risk factors are considered to be at increased risk for cardiac toxicities, and must have documented left ventricular ejection fraction (LVEF) by echocardiogram greater than institution�s lower limit of normal (or 55% if threshold for normal not otherwise specified by institutional guidelines) obtained within 3 months* Prior treatment with anthracyclines* Prior treatment with trastuzumab* A New York Heart Association (NYHA) classification of II controlled with treatment* Prior central thoracic radiation therapy (RT), including RT to the heart* History of myocardial infarction within 12 months (patients with history of myocardial infarction within 6 months are excluded from the study)Xx_NEWLINE_xXHistory of myocardial infarction within 6 months prior to registrationXx_NEWLINE_xXPatients with a significant history of cardiovascular disease (e.g., myocardial infarction [MI], thrombotic or thromboembolic event in the last 6 months)Xx_NEWLINE_xXNo history of arterial thrombotic events within the past 6 months, including:* Transient ischemic attack (TIA)* Cerebrovascular accident (CVA)* Peripheral arterial thrombus* Unstable angina or angina requiring surgical or medial intervention* Myocardial infarction (MI)* Significant peripheral artery disease (i.e., claudication on less than one block)* Significant vascular disease (i.e., aortic aneurysm, history of aortic dissection)Xx_NEWLINE_xXNo current New York Heart Association classification II, III, or IV congestive heart failureXx_NEWLINE_xXPatients must not have any clinical evidence of congestive heart failure (CHF) (specifically, New York Heart Association [NYHA] class III [moderate] or class IV [severe]) at the time of registration; baseline echocardiogram within 28 days of registration must demonstrate an ejection fraction (EF) >= 50%; patients must have corrected QT (QTc) interval < 500 msec on prestudy electrocardiogram (EKG) and no known history of congenital long QT syndrome; patients must not have experienced unstable angina pectoris, clinically significant cardiac arrhythmias, or stroke (transient ischemic attack [TIA] or other ischemic event) within 3 months prior to registration and not have experienced myocardial infarction or thromboembolic event requiring anticoagulation within 6 months of registration; prestudy EKG must be obtained within 28 days prior to registrationXx_NEWLINE_xXCurrently active clinically significant cardiovascular disease, such as uncontrolled arrhythmia, congestive heart failure, any class 3 or 4 cardiac disease, as defined by the New York Heart Association Functional Classification, or history of myocardial infarction within 6 months prior to first dose with study drugXx_NEWLINE_xXHistory of active myocardial ischemia, cardiomyopathy, uncontrolled dysrhythmia, or congestive heart failure within the last 6 months before enrollmentXx_NEWLINE_xXCardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association class III or IV), active angina pectoris, or recent myocardial infarction (within the last 6 months)Xx_NEWLINE_xXPatient history: patients who have any of the following are NOT eligible:* Central nervous system (CNS): Symptomatic, untreated, or uncontrolled brain metastases present* Heme: Active bleeding or bleeding diathesis* Gastrointestinal (GI):** Abdominal fistula, GI perforation, or intra-abdominal abscess within 28 days prior to registration** Acute GI bleed within 28 days of registration* Diabetes mellitus: Patients with diabetes mellitus with inadequate control, based on either a glycosylated hemoglobin (Hgb A1c) of > 7.0 or fasting blood glucose above or equal to 130 mg/dL* Cardiac and vascular disorders:** History of congenital long QT syndrome or torsades de pointes** Any arrhythmia that is currently not rate-controlled (rate between 60 and 100)** Prolongation of corrected QT interval via Fridericia�s formula (QTcF) > 480 msec** Ongoing unstable angina** Symptomatic peripheral vascular disease** Arterial thrombosis within 28 days of registration including transient ischemic attack (TIA), cerebrovascular accident (CVA), myocardial infarction (MI)** Patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) must be on a stable dose of anticoagulation for 14 days prior to registration** Uncontrolled hypertension, defined as blood pressure (BP) > 140/90** Multi gated acquisition scan (MUGA) with ejection fraction (EF), 50% or echocardiogram (echo) with low EF** Class III or IV congestive heart failure (CHF) within 28 days of registrationXx_NEWLINE_xXCLINICAL/LABORATORY CRITERIA: Patients must not have history of significant co-morbid illness inclusive of but not restricted to uncontrolled congestive cardiac failure, uncontrolled hypertension, history of myocardial infarction, unstable angina, coronary angioplasty, stenting or cerebrovascular accident within 6 months prior to registration or any other illness that in the assessment of the treating physician would compromise the ability of the patient to participate in this studyXx_NEWLINE_xXSevere, active co-morbidity defined as follows:* Chronic or current active infectious disease requiring systemic antibiotics, antifungal or antiviral treatment* Known brain or central nervous system metastases or history of uncontrolled seizures* Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months from enrollment, New York Heart Association class III or IV congestive heart failure, and serious arrhythmia requiring medication (this does not include asymptomatic atrial fibrillation with controlled ventricular rate)* Partial or complete gastrointestinal obstructionXx_NEWLINE_xXCardiac disease that would preclude the use of any of the drugs included in the GI002 treatment regimen; this includes but is not limited to:* Clinically unstable cardiac disease, including unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, active myocardial ischemia, or indwelling temporary pacemaker* Ventricular tachycardia or supraventricular tachycardia that requires treatment with class Ia antiarrhythmic drugs (e.g., quinidine, procainamide, disopyramide) or class III antiarrhythmic drug (e.g., sotalol, amiodarone, dofetilide); use of other antiarrhythmic drugs is permitted* Second- or third-degree atrioventricular (AV) block unless treated with a permanent pacemaker* Complete left bundle branch block (LBBB)* History of long QT syndrome* Corrected QT (QTc) >= 450msXx_NEWLINE_xXReceiving treatment for cardiomyopathy or heart failureXx_NEWLINE_xXNo history of atrial fibrillation or myocardial infarctionXx_NEWLINE_xXCongestive heart failure > New York Heart Association (NYHA) class IIXx_NEWLINE_xXMyocardial infarction or unstable angina less than 6 months before registrationXx_NEWLINE_xXSevere and/or active co-morbidity defined as follows:* History of inflammatory bowel disease* History of active hepatitis B or C; blood tests are not required to determine if the patient has had hepatitis B or C, unless the patient reports a history of hepatitis* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step 1 registration* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within 15 days of step 1 registration or precluding study therapy at the time of step 1 registration* Uncontrolled severe illness or medical condition (including uncontrolled diabetes), which in the judgment of the treating physician would make the administration of chemotherapy inadvisableXx_NEWLINE_xXSignificant cardiovascular or cerebrovascular disease including:* Uncontrolled hypertension (systolic blood pressure [SBP] >= 150; diastolic blood pressure [DBP] >= 90)* History of myocardial infarction within 6 months* Unstable angina* New York Heart Association functional classification II, III or IV* Baseline ejection fraction =< 50% as assessed by echocardiogram or multi-gated acquisition (MUGA)* Cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 6 months* Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or peripheral arterial thrombosis) within 6 monthsXx_NEWLINE_xXPatients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression, superior vena cava syndrome, symptomatic congestive heart failure, unstable angina pectoris, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent and would limit compliance with study requirementsXx_NEWLINE_xXNo clinically significant cardiac arrhythmias, stroke or myocardial infarction within 6 months prior to enrollmentXx_NEWLINE_xXPatients must have documented left ventricular ejection fraction (LVEF) by echocardiogram greater than institution�s lower limit of normal (or 55% if threshold for normal not otherwise specified by institutional guidelines) obtained within 3 months prior to registration if they have any of the following risk factors for cardiac toxicities:* A New York Heart Association (NYHA) classification of II controlled with treatment * Prior central thoracic radiation therapy (RT), including RT to the heart* History of myocardial infarction within 12 months prior to registration* Prior treatment with anthracyclines* Prior treatment with trastuzumab* Prior history of other significant impaired cardiac functionXx_NEWLINE_xXHistory of myocardial infarction within 6 months of the randomizationXx_NEWLINE_xXParticipants with any of the following:* History of myocardial infarction within six months* Unstable angina* History of cerebrovascular accident (CVA) within 6 months* New York Heart Association grade II or greater congestive heart failure* Significant vascular disease (e.g. aortic aneurysm, history of aortic dissection)* Clinically significant peripheral vascular diseaseXx_NEWLINE_xXSignificant cardiac disease or abnormality, including any one of the following:* Left ventricular ejection fraction < 50% at screening (assessed by echocardiography, cardiac MRI or multigated acquisition [MUGA])* Corrected QT Fridericia's correction formula (QTcF) > 470 ms on screening electrocardiogram (ECG), or a clinically-relevant ECG abnormality* Congenital long QT syndrome* History of sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes* Presence of atrial fibrillation with tachyarrhythmia (ventricular response rate > 100 beats per minute [bpm])* Bradycardia (heart rate < 50 bpm)* Complete left bundle branch block* Bifascicular block (complete right bundle branch block and anterior or posterior left hemiblock)* Myocardial infarction, acute coronary syndrome (including unstable angina), coronary revascularization procedures, or coronary arterial bypass grafting within the 6 months prior to starting study drug* Cardiac troponin (either troponin T or troponin I) > ULN* Congestive heart failure of New York Heart Association class III or IV* Unstable angina pectorisXx_NEWLINE_xXPatients with a known history of congestive heart failure (CHF), cardiomyopathy, myocarditis, myocardial infarction (MI), exposure to cardiotoxic medications, or with a clinical history suggestive of the above must have an electrocardiography (EKG) and echocardiogram (ECHO) performed within 42 days prior to registration and as clinically indicated while on treatmentXx_NEWLINE_xXPatients with new symptoms of congestive heart failure (CHF), cardiomyopathy, myocarditis, myocardial infarction (MI), or exposure to cardiotoxic medications must have a cardiology consultation, creatinine phosphokinase (CPK), and troponin testing at prestudy and as clinically indicatedXx_NEWLINE_xXSevere, active co-morbidity defined as follows:* Unstable angina or congestive heart failure requiring hospitalization within 6 months prior to enrollment* Transmural myocardial infarction within the last 6 months prior to registration; evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of >= 2 mm using the analysis of an electrocardiogram (EKG) performed within 28 days prior to registration (Note: EKG to be performed only if clinical suspicion of cardiac issue)* New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to registration* Serious and inadequately controlled arrhythmia at step 2 registration* Serious or non-healing wound, ulcer or bone fracture or history of abdominal fistula, intra-abdominal abscess requiring major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to registration, with the exception of the craniotomy for surgical resection* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration* Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that HIV testing is not required for entry into this protocol* Any other severe immunocompromised condition* Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity* End-stage renal disease (i.e., on dialysis or dialysis has been recommended)* Any other major medical illnesses or psychiatric treatments that in the investigator�s opinion will prevent administration or completion of protocol therapyXx_NEWLINE_xX